Sunday, November 29, 2020

AstraZeneca, Oxford Uni buoyed by ‘encouraging’ vaccine response

An AstraZeneca spokesman says the initial results 'further build the body of evidence for the safety and immunogenicity' of its experimental vaccine.

Other News

1,315 kes baru Covid-19, 1,110 pulih, 4 lagi kematian dilaporkan

Sebanyak 11,508 kes aktif direkodkan.

1,315 new cases, 476 in Sabah

Four more deaths take virus toll to 354.

Peruntukan “durian runtuh” Jasa dicantas separuh selepas nama, imej ditukar

Pengumuman pengurangan itu dijangka diumumkan ketika ucapan penggulungan peringkat jawatankuasa minggu depan.

With new name and image, Jasa’s ‘windfall’ budget to be halved

The RM85.5 million allocation, which came under criticism following its announcement on Nov 6, could be cut down by RM40 million, sources say.

Pengusaha tadika terjejas ‘terkapai-kapai’ tanpa bantuan

Pengusaha luah kekesalan kerana tidak diberikan bantuan kerajaan walaupun terjejas teruk sejak pelaksanaan Perintah Kawalan Pergerakan.

British pharma giant AstraZeneca said on Monday trials of its coronavirus vaccine pioneered with Oxford University had shown “encouraging” responses among elderly, as well as younger participants.

The potential vaccine, one of 10 around the world in the most advanced phase III of trials, showed “strong immune responses” in all adult groups during the previous stage, according to an update from Oxford.

An AstraZeneca spokesman said the initial results “further build the body of evidence for the safety and immunogenicity” of its experimental vaccine.

“It is encouraging to see immunogenicity responses were similar between older and younger adults,” the spokesman added.

The positive news emerged in data on the safety and immune responses of participants in the phase II stage of the trial Oxford has submitted for peer review in a medical journal.

They include results for UK volunteers aged 56-69 and over 70, with formal publication of the data expected “in the coming weeks”.

“Our ongoing trials will provide further data, but this marks a key milestone and reassures us that the vaccine is safe for use and induces strong immune responses in both parts of the immune system in all adult groups,” the university said.

Oxford and AstraZeneca have been trialling their potential vaccine for months in various countries around the world.

It was suspended worldwide on Sept 6 after a participant’s illness, but resumed shortly thereafter in Britain, and in the following weeks in South Africa, Brazil and Japan.

Authorities determined the illness was not apparently linked to the vaccine, with the US Food and Drug Administration also authorising the restart in the US at the weekend.

The AstraZeneca/Oxford vaccine is one of the most promising and advanced in the world to combat the global pandemic, which has now claimed the lives of 1.1 million people.

Many countries are counting on using it to inoculate their populations.

The drugmaker pre-sold hundreds of millions of doses on several continents, and signed partnership deals with other producers to ensure the doses could be made locally.

UK Health Secretary Matt Hancock further fuelled optimism Monday, noting in an interview that once approved the “bulk” of the vaccine’s rollout could occur in Britain before next summer.

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

1,315 new cases, 476 in Sabah

Four more deaths take virus toll to 354.

North Korean hackers ‘targeting AstraZeneca researchers’ for Covid-19 vaccine secrets

Cyberattacks against vaccine scientists and drug makers have soared during the Covid-19 pandemic.

New cases back to 4 digits at 1,109

However, recoveries outnumber new cases at 1,148.

Germany’s Covid-19 infections pass 1 million

The number of Covid-19 patients in intensive care nationwide has soared from just over 360 in early October to more than 3,500 last week.

935 new cases, recoveries surge to 2,555

Sabah accounts for 35% of new cases and Selangor 17%.